Initial experience with bendamustine in patients with recurrent primary central nervous system lymphoma: a case report.

17:35 EDT 17th September 2014 | BioPortfolio

Summary of "Initial experience with bendamustine in patients with recurrent primary central nervous system lymphoma: a case report."

Novel therapeutic options for patients with recurrent primary central nervous system lymphoma (RPCNSL) are needed. Bendamustine, a bifunctional purine analog/alkylating agent, is approved for use in patients with progressive systemic indolent non-Hodgkin's B-cell lymphomas. Limited data suggests that bendamustine may partition into the brain in the setting of a disrupted blood-brain barrier. This report describes the first known experience of patients with RPCNSL treated with bendamustine. Therapy was well-tolerated and best response was noted as stable disease after eight cycles of bendamustine followed by a subsequent local systemic recurrence found at five months follow-up. CNS involvement in this patient remained stable 20 + months post-bendamustine treatment. Based on our observations, further neuropharmacokinetic and efficacy studies with bendamustine may be warranted in this patient population.

Affiliation

Wake Forest School of Medicine, Winston-Salem, NC, 27157, USA.

Journal Details

This article was published in the following journal.

Name: Journal of neuro-oncology
ISSN: 1573-7373
Pages:

Links

PubMed Articles [38149 Associated PubMed Articles listed on BioPortfolio]

Management of Recurrent Iliac Artery Stenosis in Individuals Aged 55 or Less.

Aortoiliac disease is the most common location for symptomatic peripheral arterial disease in young patients. Angioplasty with stenting has become the initial treatment of choice for most patients. Ho...

A Canadian perspective on the safe administration of bendamustine and the prevention and management of adverse events.

Although bendamustine has been used to treat lymphoproliferative disorders for decades, it has only recently been approved for use in Canada. Thus, Canadian recommendations on the administration of be...

Methotrexate re-challenge for recurrent primary central nervous system lymphoma.

The prognosis of primary CNS lymphoma (PCNSL) recurring after methotrexate is poor (objective response rates [ORR] = 26-53 %; 1-year overall survival [OS] = 35-57 %). Salvage PCNSL chemotherapie...

Management of sentinel node re-mapping in patients who have second or recurrent breast cancer and had previous axillary procedures.

In patients with recurrent or second primary ipsilateral breast cancer, axillary staging is the key factor in locoregional control and a strong prognostic characteristic. The efficient evaluation of l...

Role of Pelvic Exenteration in the Management of Locally Advanced Primary and Recurrent Rectal Cancer.

A review of a single-centre experience of pelvic exenteration as a treatment modality for patients with locally advanced primary and recurrent rectal cancer. The perioperative outcomes, morbidity and ...

Clinical Trials [4165 Associated Clinical Trials listed on BioPortfolio]

Conditioning Regimen of Bendamustine and Melphalan Followed by Transplant in Patients With Multiple Myeloma

The purpose of this study is to evaluate the safety and efficacy of Bendamustine (TREANDA™), in combination with Melphalan in subjects with multiple myeloma who are undergoing an Autolog...

Open Trial of Bendamustine HCL in Women With Advanced Ovarian Cancer

The study design is a non-randomized, open label, single center Phase II trial. Eligible patients are women who have a confirmed diagnosis of ovary, fallopian tube cancer or primary perit...

Bendamustine Hydrochloride Injection for Initial Treatment of Chronic Lymphocytic Leukemia

To compare the clinical efficacy and safety of bendamustine hydrochloride versus chlorambucil for initial treatment of chronic lymphocytic leukemia

Bendamustine HCL in Relapsed and Primary Refractory Hodgkin Lymphoma

The standard treatment for patients with HL that has not responded to treatment or has come back after treatment is stem cell transplant. When patients are not eligible for transplant or w...

Lenalidomide, Bendamustine and Rituximab as First-line Therapy for Patients Over 65 Years With Mantle Cell Lymphoma.

In phase I: Establishing maximally tolerated dose of lenalidomide in combination with bendamustine and rituximab. In phase II: Evaluation of progression free survival with treatment with ...

Medical and Biotech [MESH] Definitions

Providers of initial care for patients. These PHYSICIANS refer patients when appropriate for secondary or specialist care.

A condition characterized by persistent or recurrent labial enlargement, ORAL ULCER, and other orofacial manifestations in the absence of identifiable CROHN DISEASE; or SARCOIDOSIS. There is no consensus on whether orofacial granulomatosis is a distinct clinical disorder or an initial presentation of Crohn disease.

An antiviral derivative of THYMIDINE used mainly in the treatment of primary keratoconjunctivitis and recurrent epithelial keratitis due to HERPES SIMPLEX virus. (From Martindale, The Extra Pharmacopoeia, 30th ed, p557)

Incision of Oddi's sphincter or Vater's ampulla performed by inserting a sphincterotome through an endoscope (DUODENOSCOPE) often following retrograde cholangiography (CHOLANGIOPANCREATOGRAPHY, ENDOSCOPIC RETROGRADE). Endoscopic treatment by sphincterotomy is the preferred method of treatment for patients with retained or recurrent bile duct stones post-cholecystectomy, and for poor-surgical-risk patients that have the gallbladder still present.

Polymicrobial, nonspecific vaginitis associated with positive cultures of Gardnerella vaginalis and other anaerobic organisms and a decrease in lactobacilli. It remains unclear whether the initial pathogenic event is caused by the growth of anaerobes or a primary decrease in lactobacilli.

Search BioPortfolio:
Loading